Related Experiment Video
Updated: Aug 9, 2026
09:04
Discovery of New Intracellular Pathogens by Amoebal Coculture and Amoebal Enrichment Approaches
Published on: October 27, 2013
Drug resistance in amoebiasis
Devendra Bansal1, Nancy Malla, R C Mahajan
1Department of Parasitology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
The Indian Journal of Medical Research
|April 1, 2006
Summary
Drug resistance in amoebiasis is a growing concern due to limited treatment options and the rise of resistant Entamoeba strains. New strategies are urgently needed to combat this public health challenge.
Area of Science:
- Medical Parasitology
- Infectious Diseases
- Drug Resistance Mechanisms
Background:
- Amoebiasis, caused by Entamoeba histolytica, poses a significant public health threat, particularly in developing nations.
- The morphologically similar Entamoeba dispar is non-pathogenic, complicating diagnosis and treatment strategies.
- Limited antiamoebic drug availability and the potential for increased drug resistance necessitate novel therapeutic approaches.
Purpose of the Study:
- To review the factors contributing to drug resistance in Entamoeba species.
- To highlight the public health implications of increasing antiamoebic drug resistance.
- To underscore the need for new drug development and alternative treatment strategies for amoebiasis.
Main Methods:
- This review synthesizes existing literature on amoebiasis and drug resistance.
- It examines the mechanisms by which Entamoeba parasites develop resistance to antiamoebic agents.
- The review discusses the clinical and public health consequences of treatment failures.
Main Results:
- Indiscriminate use of antiamoebic drugs can lead to elevated minimum inhibitory concentrations (MICs) against Entamoeba species.
- Treatment failures due to drug resistance are emerging as a significant public health issue.
- Current development of new antiamoebic drugs and vaccines is in its early stages.
Conclusions:
- Drug resistance in Entamoeba parasites poses a serious future threat to effective amoebiasis control.
- The development of novel antiamoebic therapies and preventative strategies is crucial.
- Addressing drug resistance is essential for managing amoebiasis as a public health problem.
Related Concept Videos
01:28Amebiasis
Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
01:30Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...